Association recommend that a dosage change and temporary or permanent (18)
discontinuance of the thiazolidinedione should be considered. If there is no evidence of heart failure, they suggest that the thiazolidinedione may be continued, with consideration of dosage reduction or addition of diuretics, and with continued observation of the oedema. Note that, in the UK rosiglitazone is contraindicated with insulin, whereas the combined metformin/rosiglitazone preparation is not. In the US pioglitazone and rosiglitazone are licenced for use with insulin.